- Home
- SBFG vs NTHI Comparison
SBFG vs NTHI Comparison
Compare SBFG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFG
- NTHI
- Stock Information
- Founded
- SBFG 1983
- NTHI 2008
- Country
- SBFG United States
- NTHI United States
- Employees
- SBFG N/A
- NTHI N/A
- Industry
- SBFG Major Banks
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SBFG Finance
- NTHI Health Care
- Exchange
- SBFG Nasdaq
- NTHI Nasdaq
- Market Cap
- SBFG 127.1M
- NTHI 142.5M
- IPO Year
- SBFG N/A
- NTHI N/A
- Fundamental
- Price
- SBFG $19.40
- NTHI $7.24
- Analyst Decision
- SBFG
- NTHI
- Analyst Count
- SBFG 0
- NTHI 0
- Target Price
- SBFG N/A
- NTHI N/A
- AVG Volume (30 Days)
- SBFG 25.0K
- NTHI 108.1K
- Earning Date
- SBFG 07-17-2025
- NTHI 01-01-0001
- Dividend Yield
- SBFG 2.99%
- NTHI N/A
- EPS Growth
- SBFG N/A
- NTHI N/A
- EPS
- SBFG 1.70
- NTHI N/A
- Revenue
- SBFG $58,813,000.00
- NTHI $79,990.00
- Revenue This Year
- SBFG N/A
- NTHI N/A
- Revenue Next Year
- SBFG N/A
- NTHI N/A
- P/E Ratio
- SBFG $11.41
- NTHI N/A
- Revenue Growth
- SBFG 5.03
- NTHI 13.52
- 52 Week Low
- SBFG $13.20
- NTHI $4.11
- 52 Week High
- SBFG $24.48
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SBFG 47.65
- NTHI N/A
- Support Level
- SBFG $19.02
- NTHI N/A
- Resistance Level
- SBFG $19.88
- NTHI N/A
- Average True Range (ATR)
- SBFG 0.55
- NTHI 0.00
- MACD
- SBFG -0.01
- NTHI 0.00
- Stochastic Oscillator
- SBFG 39.37
- NTHI 0.00
About SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").